RECURRENT CANCER

This study tests a personalized vaccine made from your tumor's unique mutations. It aims to train your immune system to attack cancer cells. The trial includes 10 adults with advanced or high-risk solid tumors. Participants receive the vaccine plus immune-boosting drugs over seve…

This early-phase trial tests an experimental drug called IMA402 in about 145 adults with solid tumors that have returned or not responded to standard treatments. The drug is designed to help the immune system find and attack cancer cells that carry a protein called PRAME. The mai…

This study tests a drug called cabozantinib in 20 adults whose liver cancer came back after a liver transplant. The goal is to see if the drug can control the cancer and slow its growth. Participants take the drug until it stops working or side effects become too severe.

This study tests new cancer drugs that are chosen based on the unique genetic makeup of each child's tumor. It is for children, teens, and young adults with advanced solid tumors, brain tumors, or lymphomas that have not responded to standard treatments. The goal is to find the r…

This study tests a new treatment for adults with solid tumors that have come back or not responded to standard therapies. The treatment uses a patient's own immune cells that are genetically modified to recognize and attack cancer cells. Some participants will also receive the dr…

This study tests a new radiation method for people with cervical cancer or pelvic cancer that has come back. It is for those who cannot get standard brachytherapy because of unusual anatomy or large tumors. The goal is to see if this technique can control the cancer in the treate…

This study tests a combination of three drugs (pembrolizumab, ibrutinib, and rituximab) in people whose primary central nervous system lymphoma has come back or not responded to prior treatment. The goal is to see if the combo can control the cancer for at least 6 months. About 3…